SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parmax Pharma informs about trading window closure

30 Dec 2025 Evaluate
In terms of provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company’s Code of Conduct to regulate, monitor and report trading by Designated Persons, Parmax Pharma has informed that the Trading Window for dealing in securities of the Company by Designated Persons shall remain closed from January 01, 2026 till 48 hours after the declaration of the financial results for the quarter ending on December 31, 2025 for all designated persons of the Company. The date of the Board Meeting at which the said results will be considered shall be intimated in due course of time.

The above information is a part of company’s filings submitted to BSE.

Parmax Pharma Share Price

30.02 -0.98 (-3.16%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×